Definition:Third-party consent
🤝 Third-party consent is the formal approval required from an external party — neither the buyer nor the seller — before certain actions in an insurance transaction or contractual arrangement can proceed. In insurance M&A and corporate restructurings, the need for third-party consents frequently arises because insurance businesses operate within dense webs of contractual relationships: binding authority agreements with carriers, reinsurance treaties, brokerage appointments, outsourced claims handling contracts, technology licenses, and bank credit facilities often contain anti-assignment or change-of-control clauses that require the counterparty's consent before the agreement can transfer or remain in effect under new ownership.
📋 Identifying and securing third-party consents is a critical workstream in any insurance deal's due diligence and pre-closing execution phase. The buyer's advisers will review the target's material contracts to catalogue every consent requirement, assess the risk that a counterparty might withhold consent or use the leverage to extract better terms, and prioritize outreach accordingly. In practice, the most sensitive consents in insurance transactions involve capacity providers — if a carrier relationship that underpins a MGA's book of business requires consent for a change of control, and the carrier is reluctant or slow to grant it, the deal can stall or collapse. Reinsurance treaty consents pose similar challenges, particularly for quota share arrangements where the reinsurer has underwritten the risk based on confidence in the ceding company's existing management team. The share purchase agreement typically addresses consent risk through conditions precedent (requiring key consents before closing) or through indemnification provisions that allocate the economic cost of lost contracts if consents are not obtained.
⚠️ Regulatory approvals represent another layer of third-party consent that is especially prominent in insurance. Most jurisdictions require prior approval from the insurance regulator for any change of control of a licensed insurer — in the United States, this involves filings under the Insurance Holding Company System Regulatory Act with the relevant state insurance departments; in the EU, Solvency II Directive provisions govern qualifying holdings; and in markets like Hong Kong and Singapore, the Insurance Authority or MAS must approve significant ownership changes. Unlike commercial counterparty consents, regulatory approvals are non-negotiable and cannot be waived by the parties. The timeline for obtaining regulatory consent varies widely — from weeks for straightforward transactions in well-staffed regulatory jurisdictions to many months for complex cross-border deals — and frequently dictates the overall transaction timeline. Failure to anticipate and manage both commercial and regulatory third-party consent requirements is one of the most common sources of delay and value destruction in insurance M&A.
Related concepts: